Stifel Financial Corp Cuts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Stifel Financial Corp reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 32.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,917 shares of the company’s stock after selling 20,062 shares during the quarter. Stifel Financial Corp’s holdings in Moderna were worth $2,801,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of MRNA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after acquiring an additional 19,819 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Moderna by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,132,777 shares of the company’s stock valued at $142,533,000 after buying an additional 83,082 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares in the last quarter. Finally, Bellevue Group AG increased its stake in shares of Moderna by 2.4% during the third quarter. Bellevue Group AG now owns 1,600,836 shares of the company’s stock worth $106,984,000 after buying an additional 37,101 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,379 shares of company stock valued at $158,195 over the last ninety days. Corporate insiders own 15.20% of the company’s stock.

Moderna Trading Down 5.9 %

Shares of MRNA stock opened at $38.36 on Thursday. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $47.16 and its two-hundred day moving average is $81.43. The company has a market capitalization of $14.76 billion, a P/E ratio of -6.59 and a beta of 1.58.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the previous year, the company posted ($1.39) EPS. Moderna’s revenue was up 3.8% compared to the same quarter last year. Equities analysts forecast that Moderna, Inc. will post -9.3 EPS for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of recent analyst reports. The Goldman Sachs Group dropped their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a report on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Monday, November 18th. Finally, Jefferies Financial Group dropped their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.50.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.